Meta‐analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Aim: To estimate absolute and relative incidence rates of hypoglycaemia when using once‐daily evening or morning regimens of insulin glargine (glargine) versus once‐daily evening NPH insulin (NPH) using individual patient data (IPD). Materials and methods: Randomized controlled trials with accessible IPD and including white European people with type 2 diabetes (T2DM) using glargine or NPH once‐daily (with oral glucose‐lowering drugs) were identified. Two study pools were analysed: evening glargine versus evening NPH (pool 1); and morning glargine versus evening NPH (pool 2). The number‐needed‐to‐treat to avoid hypoglycaemia was calculated for glargine versus NPH. Results: In study pool 1 (n = 2711), the risk of nocturnal hypoglycaemia was approximately halved with glargine compared with NPH [odds ratios (OR): 0.44–0.52, p < 0.001–0.047]. This led to a significant reduction in anytime risk of symptomatic hypoglycaemia [plasma glucose (PG) <3.9 mmol/l, OR: 0.64, p = 0.018; PG <2.0 mmol/l, OR: 0.51, p < 0.001]. In study pool 2 (n = 470), although a strong numerical reduction in all types of nocturnal hypoglycaemia was observed (OR: 0.16–0.64), statistical significance was reached only for symptomatic hypoglycaemia with PG <3.9 mmol/l (p < 0.001). Eight (pool 1) or five (pool 2) people with T2DM needed to use glargine rather than NPH to avoid one person from experiencing a nocturnal symptomatic hypoglycaemic event within a median of about 25 weeks of starting insulin. Conclusions: This meta‐analysis of open‐label studies provides confidence that reductions of around 50% of risk for nocturnal hypoglycaemia can be achieved with using glargine instead of NPH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
The number needed to treat: a clinically useful measure of treatment effect
Cook, R. J., & Sackett, D. L. (1995) · BMJ · doi:10.1136/bmj.310.6977.452 · Cited by 1,885 · cited 1×
“The NNT was calculated using the formula NNT = 1/(pN − pG), where pN and pG are the absolute risks of at least one hypoglycaemic episode in a person receiving NPH or glargine, respectively [32].”
MethodMoher, D., Schulz, K. F., Altman, D. G., & for the CONSORT Group* (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-8-200104170-00011 · Cited by 1,426
Controlling the risk of spurious findings from meta-regression
Higgins, J. P. T., & Thompson, S. G. (2004) · Statistics in Medicine · doi:10.1002/sim.1752 · Cited by 1,267
Stratton, I. M., Kohner, E. M., Aldington, S. J., Turner, R. C., Holman, R. R., Manley, S. E., & Matthews, D. R. (2001) · Diabetologia · doi:10.1007/s001250051594 · Cited by 1,019
Bonds, D. E., Miller, M. E., Bergenstal, R. M., Buse, J. B., Byington, R. P., Cutler, J. A., Dudl, R. J., Ismail-Beigi, F., Kimel, A. R., Hoogwerf, B., et al. (2010) · BMJ · doi:10.1136/bmj.b4909 · Cited by 933
Fear of hypoglycemia: quantification, validation, and utilization
Cox, D. J., Irvine, A., Gonder-Frederick, L., Nowacek, G., & Butterfield, J. (1987) · Diabetes Care · doi:10.2337/diacare.10.5.617 · Cited by 579
Hypoglycaemia in Type 2 diabetes
Amiel, S. A., Dixon, T., Mann, R., & Jameson, K. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02341.x · Cited by 472
Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study
Yki-Järvinen, H., Kauppinen-Mäkelin, R., Tiikkainen, M., Vähätalo, M., Virtamo, H., Nikkilä, K., Tulokas, T., Hulme, S., Hardy, K., McNulty, S., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0132-0 · Cited by 434 · cited 1×
“RESULTS Study Population Six studies comparing once-daily evening regimens of glargine and NPH in people with T2DM (pool 1) were identified from the literature analysis; however, one of these [33] was excluded because of unavailability of IPD on details of hypoglycaemia.”
Background
Research works printed but not linked: 31
- 10.1002/dmrr.796 · DOI · Paper page
- MacLeod KM., 2000, Hypoglycaemia unawareness: causes, consequences and treatment, J R Coll Physicians Lond, 34, 245
- 10.3949/ccjm.71.4.335 · DOI · Paper page
- 10.1185/030079905X61929 · DOI · Paper page
- 10.1093/eurheartj/ehi230 · DOI · Paper page
- 10.1016/S0140-6736(09)60697-8 · DOI · Paper page
- 10.1016/S0140-6736(01)05842-1 · DOI · Paper page
- 10.2337/diacare.26.11.3080 · DOI
- 10.1055/s-2003-39080 · DOI · Paper page
- 10.2337/diacare.24.4.631 · DOI · Paper page
- 10.2337/diacare.23.8.1130 · DOI · Paper page
- 10.7326/0003-4819-138-12-200306170-00006 · DOI · Paper page
- 10.1016/j.clinthera.2007.08.020 · DOI
- 10.1016/j.beem.2007.08.002 · DOI
- 10.1016/S0149-2918(07)80086-5 · DOI
- 10.5414/CPP45203 · doi:10.5414/cpp45203
- 10.1016/S0895-4356(01)00414-0 · DOI · Paper page
- 10.1002/sim.1023 · DOI · Paper page
- 10.7326/0003-4819-134-8-200104170-00012 · DOI · Paper page
- 10.1016/S0140-6736(99)04149-5 · DOI · Paper page
- The Cochrane Collaboration., Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 (updated September 2006).
- 10.1002/sim.1186 · DOI · Paper page
- 10.1002/sim.1186 · DOI · Paper page
- 10.1016/j.arcmed.2005.10.015 · DOI
- 10.1016/j.diabres.2006.08.012 · DOI
- 10.1056/NEJM199806043382303 · DOI · Paper page
- 10.1097/01.jom.0000161727.03431.3e · DOI · Paper page
- Heaton A, 2003, The economic effect of hypoglycemia in a health plan, Manag Care Interface, 16, 23
- 10.1007/s10198-005-0276-3 · DOI · Paper page
- National Institute for Health and Clinical Excellence (NICE)., Type 2 diabetes. National clinical guideline for management in primary and secondary care (update) Appendix C: Health exonomic analysis of third‐line therapy with insulins glitazones or exematide in Type 2 diabetes.
- National Institute for Health and Clinical Excellence (NICE)., Appendix 2‐ Technology assessment report. Type 2 diabetes: new agents.
Cited by
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2016) · Endocrine Practice · doi:10.4158/ep151126.cs · Cited by 878
Update on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
“The risk of hypoglycaemia and weight gain will be lower with the use of insulin analogues compared to human insulins, and are preferred in elderly, despite their higher cost [208,269] , especially if there is a high risk of hypoglycaemia as in the frail or institutionalized elderly.”
BackgroundHandelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Metadata
- Authors
- Home, P. D., Fritsche, A., Schinzel, S., & Massi‐Benedetti, M.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2010-07-23
- Volume
- 12
- Issue
- 9
- Pages
- 772-779
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W1978822680
- Cited by
- 96
- References
- 11
- FWCI
- 8.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Meta‐analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine. https://app.cochat.ai/papers/10.1111/j.1463-1326.2010.01232.x
- The paper
- Home, P. D., Fritsche, A., Schinzel, S., & Massi‐Benedetti, M. (2010). Meta‐analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2010.01232.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.